Pasi A. Jänne, MD, PhD - A Visual Exploration of New Targeted Therapies for EGFR Exon 20 Insertions in NSCLC: The Latest Evidence and Practical Guidance for Biomarker Testing and Individualized Treatm

Go online to PeerView.com/AYJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this engaging and animated activity, an expert on EGFR exon 20 insertion–positive NSCLC discusses the role of biomarker testing and examines the evidence for new and emerging therapies to offer patient-centered guidance on individualizing care and improving outcomes. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of EGFR mutations in NSCLC, frequency and characteristics of EGFR exon 20 insertion mutations, latest evidence and guidelines on targeted therapies in this setting, and importance of biomarker testing to identify patients for these therapies in clinical practice; Apply multidisciplinary strategies for biomarker testing and targeted treatment selection and sequencing to optimize therapeutic outcomes in patients with NSCLC harboring EGFR exon 20 insertion mutations; and Engage patients with EGFR exon 20 insertion–positive NSCLC in shared decision-making regarding available targeted therapy options to ensure individualized treatment selection that aligns with their needs, values, and preferences